GlassScriptPhysician profile
Lisa Hammock
NPI 1366968729
$5,174.13
in general payments reported to CMS, 2019-2025
26 companies · $893 in 2025
The $893 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,192 · 2022: $887 · 2023: $1,037 · 2024: $1,166 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $736.82 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $713.73 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $688.63 | 2021-2025 | |
| Lilly USA, LLC | $430.38 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Amarin Pharma, INC. | $353.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $335.77 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.50 | 2021-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $276.61 | 2022-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $237.48 | 2022-2025 | |
| Zealand Pharma US, INC. | $164.45 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.03 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $103.64 | 2021-2022 | |
| Pfizer INC. | $95.98 | 2021-2025 | |
| Antares Pharma, INC. | $68.08 | 2021-2025 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $62.00 | 2023-2025 | Livalo, Seglentis, Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $61.51 | 2021-2022 | |
| Glaxosmithkline, LLC. | $58.05 | 2021-2022 | |
| Corcept Therapeutics | $52.64 | 2025 | Korlym |
| Exact Sciences Corporation | $51.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $51.02 | 2023 | Verquvo, Steglatro, Belsomra |
| Kyowa Kirin, INC. | $42.07 | 2024 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.75 | 2024 | Caplyta |
| Ibsa Pharma INC. | $36.40 | 2022 | |
| Abbott Laboratories | $24.80 | 2021 | |
| Genentech USA, INC. | $18.02 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hammock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.